These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21885275)

  • 1. Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.
    Johnson PS; Ryckmans T; Bryans J; Beal DM; Dack KN; Feeder N; Harrison A; Lewis M; Mason HJ; Mills J; Newman J; Pasquinet C; Rawson DJ; Roberts LR; Russell R; Spark D; Stobie A; Underwood TJ; Ward R; Wheeler S
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5684-7. PubMed ID: 21885275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series.
    Achermann G; Ballard TM; Blasco F; Broutin PE; Büttelmann B; Fischer H; Graf M; Hernandez MC; Hilty P; Knoflach F; Koblet A; Knust H; Kurt A; Martin JR; Masciadri R; Porter RH; Stadler H; Thomas AW; Trube G; Wichmann J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5746-52. PubMed ID: 19726184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).
    Russell R; Doyle R; Turner J; Attkins N; Ramsey S; Weibley L; Bateman L; Bictash M; Neal-Morgan S; Ivarsson M; Pullen N
    Eur J Pharmacol; 2011 Nov; 670(2-3):347-55. PubMed ID: 21958878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin antagonists.
    Lemmens-Gruber R; Kamyar M
    Cell Mol Life Sci; 2006 Aug; 63(15):1766-79. PubMed ID: 16794787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
    Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
    Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction.
    Buettelmann B; Ballard TM; Gasser R; Fischer H; Hernandez MC; Knoflach F; Knust H; Stadler H; Thomas AW; Trube G
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5958-61. PubMed ID: 19740657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene.
    Mayinger B; Hensen J
    Exp Clin Endocrinol Diabetes; 1999; 107(3):157-65. PubMed ID: 10376439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
    Napier S; Wishart G; Arbuckle W; Baker J; Barn D; Bingham M; Brown A; Byford A; Claxton C; Craighead M; Buchanan K; Fielding L; Gibson L; Goodwin R; Goutcher S; Irving N; MacSweeney C; Milne R; Mort C; Presland J; Sloan H; Thomson F; Turnbull Z; Young T
    Bioorg Med Chem Lett; 2011 May; 21(10):3163-7. PubMed ID: 21458261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
    Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
    Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY; Wo NC; Cheng LL; Manning M
    J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.
    Matthews JM; Hoekstra WJ; Dyatkin AB; Hecker LR; Hlasta DJ; Poulter BL; Andrade-Gordon P; de Garavilla L; Demarest KT; Ericson E; Gunnet JW; Hageman W; Look R; Moore JB; Reynolds CH; Maryanoff BE
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2747-52. PubMed ID: 15125926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior.
    Ferris CF; Lu SF; Messenger T; Guillon CD; Heindel N; Miller M; Koppel G; Robert Bruns F; Simon NG
    Pharmacol Biochem Behav; 2006 Feb; 83(2):169-74. PubMed ID: 16504276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging.
    Haider A; Xiao Z; Xia X; Chen J; Van RS; Kuang S; Zhao C; Rong J; Shao T; Ramesh P; Aravind A; Shao Y; Ran C; Young LJ; Liang SH
    Pharmacol Res; 2021 Nov; 173():105886. PubMed ID: 34536549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile diverted synthesis of pyrrolidinyl triazoles using organotrifluoroborate: discovery of potential mPTP blockers.
    Jung Sh; Choi K; Pae AN; Lee JK; Choo H; Keum G; Cho YS; Min SJ
    Org Biomol Chem; 2014 Dec; 12(47):9674-82. PubMed ID: 25348904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and discovery of 1,3-benzodiazepines as novel dopamine antagonists.
    Zhu Z; Sun ZY; Ye Y; McKittrick B; Greenlee W; Czarniecki M; Fawzi A; Zhang H; Lachowicz JE
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5218-21. PubMed ID: 19643610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.
    Arbuckle W; Baker J; Barn D; Bingham M; Brown A; Buchanan K; Craighead M; Goodwin R; Goutcher S; Kiczun M; Lyons A; Milne R; Montgomery B; Napier S; Presland J; Sloan H; Turnbull Z; Wishart G
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4622-8. PubMed ID: 21700453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction.
    Knust H; Achermann G; Ballard T; Buettelmann B; Gasser R; Fischer H; Hernandez MC; Knoflach F; Koblet A; Stadler H; Thomas AW; Trube G; Waldmeier P
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5940-4. PubMed ID: 19762240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.